The US Food and Drug Administration (FDA) has granted 510(k) clearance for Johnson & Johnson (J&J) MedTech’s Monarch Quest ...

Lifeward announced today that it received FDA 510(k) clearance for its latest-generation personal exoskeleton device, ReWalk ...

Spineart and eCential Robotics today announced the receipt of FDA 510(k) clearance for the use of an application for robotic ...

The Company continues to make steady progress toward commercial readiness, and key clinical and regulatory milestones on the ...

Lifeward stock is trading higher on Thursday after the company announced that its ReWalk 7 received 510(k) clearance from the ...

FDA clearance for the newest generation of its personal exoskeleton device, the ReWalk 7. The seventh generation of the ReWalk, a wearable exoskeleton that allows individuals with spinal cord injury ...

Perfuze, an Ireland-based developer of catheter-based aspiration technology for the treatment of acute ischemic stroke, ...

Last week, Lifeward said full-year revenue rose to $25.7 million from $13.9 million. It said ReWalk Personal Exoskeleton sales increased by 130% in 2024, fueled by recently established Medicare ...

The number of single-use handpiece units shipped in Q4 2024 exceeded expectations, increasing 5% overall and 20% in the U.S. compared to the same period last yearSubmitted a 510(k) premarket notificat ...

The global ultrasound image analysis software market is being significantly propelled by advancements in ultrasound ...

Liquidmetal Technologies, Inc. ( OTCQB:LQMT) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Good afternoon. Welcome to the Liquidmetal Technologies Fiscal Year 2024 Conference Call. My ...

Morgans analyst Scott Power notes there's a risk-off sentiment among investors as ASX health stocks fall again this week.